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826-4 B-Type Natriuretic Peptide Levels on Admission Predict 
Short-Term Mortality and Angiographic Success of 
Procedure in Patients With Acute ST Elevation 
Myocardial Infarction Treated With Primary Angioplasty
Marcin Grabowski, Krzysztof J. Filipiak, Grzegorz Karpinski, Adam Rdzanek, Arkadiusz 
Pietrasik, Zenon Huczek, Grzegorz Horszczaruk, Janusz Kochman, Grzegorz Opolski, 
Medical University of Warsaw, Warsaw, Poland
Background: B-type natriuretic peptide (BNP) levels in the first days after the onset of
symptoms are predictive of short-term mortality in patients with acute coronary syn-
dromes. Few data are available for BNP levels obtained on admission in patients (pts)
with acute ST elevation myocardial infarction (STEMI). Methods: Blood samples for BNP
determination were obtained on admission in 117 pts (mean age 58,4±10,7 years old)
with STEMI. In a 15-minute period, BNP was measured by using simple bedside test for
rapid quantification of BNP, before primary percutaneus coronary intervention (PCI). 30
days follow-up was performed. PCI was performed in all (100%) pts. Results: Mean for
BNP was 171,8±218,2 pg/ml. Baseline level of BNP was higher among pts who died than
among those who were alive at 30 days (median, 541,9±247,2pg/ml vs. 140,9±185,9 pg/
ml; p<0,001). Baseline BNP in subgroups by median level showed a significant increase
in mortality: 1 (1%) in inframedian group (IMG) vs. 8 (13%) in supramedian group (SMG)
(p<0,05). Baseline level of BNP in subgroups by Killip class on admission was higher
among pts who died than among those who were alive at 30 days (Killip class I: median,
475,8± 280,6 pg/ml vs. 123,6±138,1 pg/ml p<0,05; Killip class II-IV: 257,1± 362,5 pg/ml
vs. 624,5± 203,9 pg/ml, p=0,01). After adjustment for independent predictors of risk of
death, the odds ratio for death at 30 days in SMG was 13,6 (95% confidence interval, 1.1
to 182.7). There was no difference in subgroups by median BNP in TIMI 3 flow grade
before PCI (7% vs. 7%; p=NS). TIMI 3 after PCI was more often seen in pts in IMG vs.
SMG (90% vs. 72%, p=0,01). BNP was higher among pts with TIMI 0, 1 or 2 after PCI
than among pts with TIMI 3 after PCI (328,3±332,8 pg/ml vs. 151,32±196,7 pg/ml;
p<0,01). BNP remained independent predictor for TIMI 0, 1 or 2 after PCI (odds ratio in
SMG was 3,5 (95% confidence interval 1,2 to 10,8). Conclusion: BNP levels obtained on
admission are powerful, independent indicator of short-term mortality and angiographic
success after PCI in pts with STEMI. Rapid tests for BNP assay seem to be new tool in
risk stratification of pts with STEMI.
5:00 p.m.
826-5 Profiling Inflammation in the Ischemic Human Heart In 
Vivo
Anders Gabrielsen, Patrick Lawler, Jesper Haeggström, Gabrielle Berne Paulsson, Wang 
Yongzhong, Daniel Steinbruchel, Jens Kastrup, Goran Hansson, Karolinska Institute, 
Stockholm, Sweden, Copenhagen University Hospital, Copenhagen, Denmark
Background: The present understanding of myocardial inflammation and its potential
role in myocardial pathophysiology is incomplete. Therefore, we used Affymetrix® Gene-
Chip analysis on normal and chronic ischemic myocardium before and during acute
ischemia and reperfusion stress to profile expression of inflammation-related transcripts.
Methods: Biopsies were sampled at baseline, after 45 min of acute total ischemia, and
after 30 min of reperfusion recovery from normally perfused and chronic reversibly
ischemic myocardium in 6 patients undergoing coronary artery by-pass grafting. RNA
was isolated, amplified with established techniques, and hybridized to HG_U133A
Affymetrix® Genechip arrays. A total of 33 arrays were performed, normalized with the
RMA algorithm, and analyzed for expression patterns of pro- and anti-inflammatory fac-
tors.
Results: At baseline, expression of 5-lipoxygenase, MCP-1 and IL-6 was higher in
chronic ischemic myocardium than in normally perfused myocardium. In response to
acute ischemia and reperfusion in the normal myocardium, there was a clear trend
towards increased expression of pro-inflammatory factors (e.g. 5-lipoxygenase, COX-2,
CysLT2 receptor, MCP-1, IL-6). These responses were less pronounced or detectably
absent in the chronic ischemic myocardium.
Conclusion: These findings suggest a discrete increase in several pro-inflammatory fac-
tors that may contribute to myocardial pathophysiology in chronic myocardial ischemia.
The blunted inflammatory response to acute ischemia in the chronic ischemic myocar-
dium may suggest altered sensitivity in signaling pathways mediating the inflammatory
response.
5:15 p.m.
826-6 Hyponatremia: A Useful Marker for Early Risk 
Assessment in Acute ST Elevation Myocardial Infarction
Alexander Goldberg, Haim Hammerman, Sirouch Petcherski, Sergey Yalonetsky, 
Alexander Zdorovyak, Michael Kapeliovich, Walter Markiewicz, Doron Aronson, Rambam 
Medical Center, Haifa, Israel, Rappaport Medical School, Haifa, Israel
Background: Hyponatremia (HNa) is common in hospitalized patients and is associated
with adverse prognosis, especially in heart failure. Data on the prevalence and prognostic
significance of HNa in the setting of acute ST-elevation myocardial infarction (STEMI) is
sparse.
Methods: We studied 1047 consecutive patients (pts) (age 60 ± 12) presenting with
STEMI. Plasma sodium concentrations (PNa) were obtained on admission and at 24-h,
48-h, and 72-h. Multiple logistic regression was performed to determine the relation
between HNa and 30-day mortality adjusting for age, sex, diabetes, hypertension, smok-
ing, Killip class, peak CK, LVEF, anterior infarction, use of diuretics and reperfusion ther-
apy.
Results: HNa (PNa < 135 mmol/L) was present on admission in 131 pts (12.5%) and
developed in 208 (19.9%) during the first 72-h. PNa decreased to <130 mmol/L in 75
(7.2%) of pts. Pts receiving diuretics developed HNa more commonly compared to pts
who were not (46% vs 28%, p< 0.0001), but the majority of hyponatremic pts (66%) were
not receiving diuretics. Kaplan-Meyer curves indicated that pts with HNa were at
increased risk of mortality (Figure). HNa on admission (OR 2.2, 95% CI 1.2-4.2, p=
0.015) and HNa developing early after admission (OR 2.7, 95% CI 1.6-4.6, p< 0.0001)
were independent predictors of 30-days mortality.
Conclusion: HNa on admission, or early development of HNa in patients with STEMI is
a strong independent predictor of 30-day mortality. PNa may serve as a simple marker to
identify patients at high risk. 
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827-2 Fasting Glucose Is an Independent Predictor of 30-Day 
Mortality in Nondiabetic Patients With Acute Myocardial 
Infarction: A Prospective Study
Mahmoud Suleiman, Walter Markiewicz, Michael Kapeliovich, Haim Hammerman, Doron 
Aronson, Rambam Medical Center, Haifa, Israel
Background: Studies have suggested that hyperglycemia may increase mortality after
acute myocardial infarction (AMI). However, these studies have not adjusted for important
determinants of prognosis and hyperglycemia was defined arbitrarily as a dichotomous
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Methods: We prospectively enrolled 535 non-diabetic patient (pts) with AMI (age 60 ±
13). Fasting glucose (FG) was measured on the first morning after admission, and
divided into tertiles. Ejection fraction (EF) was determined by echocardiography on day 2
or 3. Adjusted 30-day mortality was evaluated using multiple logistic regression with the
following covariates: age, gender, hypertension, smoking, prior AMI, Killip class, heart
rate and systolic blood pressure, ST-elevation infarction, anterior infarction, peak CK, and
use of reperfusion therapy.
Results: At 30 days, 6 deaths (3%) occurred in pts in the lowest FG tertile (<98 mg/dL),
11 (6%) in pts in the middle FG tertile (98-118 mg/dL), and 35 (20%) in pts in the highest
FG tertile (>118 mg/dL) (Figure). The risk of 30-day mortality increased with increasing
tertiles of FG (P trend = 0.02), with an OR of 3.2 for pts in the upper FG tertile (95% CI
1.5-6.8, p = 0.002). Further adjustment for EF gave similar results (OR = 2.8, 95% CI 1.3-
6.2, p = 0.01).
Conclusion: In pts with AMI stress hyperglycemia is a strong predictor of 30-day mortal-
ity independent of infarct size and other traditional predictors of outcome. Increased risk
appears to be associated even with FG in the upper normal range.
4:30 p.m.
827-3 Women With Diabetes Mellitus Have the Greatest 
Reduction in Myocardial Infarction Mortality Over the 
Past Decade: Evaluation of 1,428,596 Patients Enrolled 
in the National Registry of Myocardial Infarction 2, 3, 
and 4 From 1994-2002
Darren K. McGuire, Amit Khera, James A. de Lemos, Eric D. Peterson, John J. Warner, 
Lori S. Parsons, William J. Rogers, John G. Canto, for the National Registry of 
Myocardial Infarctions Investigators, University of Texas-Southwestern Medical Center, 
Dallas, TX, University of Alabama, Birmingham, AL
Background: Analyses from NHANES showed a decline in cardiovascular (CV) mortality
in the 1970s-80s, but among patients with diabetes mellitus (DM), the rate of decline was
attenuated among men (less improvement) and women (no improvement). We sought to
examine the relation between sex, DM, and hospital mortality in the setting of contempo-
rary care for myocardial infarction (MI).
Methods/Results: We analyzed data from 1,428,596 patients with MI enrolled in NRMI
2, 3, & 4 from 1994-2002. DM was present in 410,223 patients (29%), increased in prev-
alence over the study period (26% to 31%), and was associated with higher adjusted
hospital mortality (13.8% vs. 10.9%; adjusted OR=1.3 [95% CI 1.3-1.33]. Use of ASA, β-
blockers, and ACE inhibitors within 24 hours of admission increased yearly for both DM
and non-DM cohorts. Overall hospital mortality declined between 1994-2002 (19.7%; p
for trend<0.001), with a greater rate of decline among DM vs. non-DM patients (26.4%
vs. 17.9% reduction). Hospital mortality declined in all subsets of women and men with
and without DM (Figure), with the greatest mortality improvement among women with DM
(30.9% reduction; p for trend<0.001)).
Conclusions: Between 1994-2002, MI hospital mortality declined among patients with
and without DM, associated with increasing use of evidence-based CV therapies.
Patients with DM had the greatest mortality improvement, and contrary to the earlier
NHANES findings, women with DM have recently experienced the greatest mortality
improvement.
4:45 p.m.
827-4 N Terminal Pro Brain Natriuretic Peptide Is the Most 
Powerful Predictor of Long-Term Mortality in Diabetic 
Patients With Acute Coronary Syndromes
Stefan Karl James, Mats Stridsberg, Per Venge, Paul Armstrong, Robert Califf, Maarten 
Simoons, Lars Wallentin, Institution of Medical Sciences, Uppsala, Sweden
Background: Acute coronary syndrome (ACS) patients with diabetes have increased
morbidity and mortality. The individual factors contributing to this are incompletely under-
stood.
Methods: We evaluated predictors of outcome in 1677 patients with diabetes in the inter-
national GUSTO IV trial that enrolled 7800 ACS patients without ST-elevation not sched-
uled for early revascularization.
Results:
The incidence of myocardial infarction at 30 days in patients with diabetes tended to be
higher than for non-diabetics; 6.4% vs. 5.3%, p=0.09. The mortality was however, almost
twice as high; at 30 days 6.0% vs. 3.2%, p<0.001) and at 1-year, 13.5% vs. 6.9%
p<0.001. On multivariate analysis including a large number of predictors of mortality, lev-
els of N-terminal proBrain Natriuretic (Nt-proBNP) peptide was the risk-indicator with the
strongest relation to long-term mortality.
Conclusion: In patients with diabetes mellitus and non-ST elevation ACS, mortality is
substantially increased. Also in diabetic patients the utilization of a multi-marker strategy
can select patients at highest risk for an intensified treatment.
5:00 p.m.
827-5 Diabetic Patients With Acute Myocardial Infarction Have 
Larger Infarct Size, Lower Ejection Fraction, and Higher 
Mortality
Jorge R. Alegria, Todd D. Miller, Raymond J. Gibbons, Qi-Long Yi, Salim Yusuf, Mayo 
Clinic, Rochester, MN, McMaster Clinic, Hamilton, ON, Canada
Introduction: Patients with diabetes mellitus (DM) with acute myocardial infarction (AMI)
have a higher mortality than non-diabetics (NoDM). The aim of this study was to examine
the relationships between mortality, left ventricular ejection fraction (LVEF), and infarct
size in patients with DM with AMI. Methods: In the Collaborative Organization of Rheo-
thRx Evaluation (CORE) Trial, subsets of patients underwent quantitative radionuclide
measurement of gated equilibrium LVEF (n=1139), Technetium-99m sestamibi infarct
size (n= 1167), or both (n=872) at days 6-16 following thrombolysis for AMI. Follow-up at
6 months was 96.7% complete. Results: The prevalence of DM in these patient subsets
was 16%-17%. Patients with DM had evidence for larger infarcts even after adjustment
baseline variables: mean LVEF 48% DM vs 51% NoDM (p=0.0021); infarct size (% of left
ventricle) 22% DM vs 17% NoDM (p=0.0396). The number of deaths was small in both
groups: LVEF subset = 21, infarct size subset = 27. Six-month mortality was higher in
patients with DM: LVEF subset 6% DM vs 1% NoDM; infarct size subset 6% DM vs 2%
NoDM. In the LVEF subset, both DM (p< 0.0001) and LVEF (p=0.0002) were indepen-
dent predictors of mortality; similarly, in the infarct size subset, DM (p=0.0028) and infarct
size ( p=0.0024) were independent predictors. Conclusions: Patients with DM with AMI
have lower LVEF and larger infarct size. Larger infarction only partially explains the
higher mortality in patients with DM, since DM itself was associated with higher 6-month
mortality independent of LVEF or infarct size.
5:15 p.m.
827-6 Underuse of Glycoprotein IIb/IIIa Receptor Blockers in 
Diabetics Undergoing Percutaneous Coronary 
Intervention for Acute Coronary Syndromes in Current 
Clinical Practice in Europe: Results of the International 
Shakespeare Registry
Anselm K. Gitt, Uwe Zeymer, Martin G. Gottwik, Jean-Pierre Bassand, Keith Dawkins, 
David Hasdai, Ricardo Seabra-Gomes, Andreij Cieslinski, Paolo Fioretti, Jochen Senges, 
The SHAKESPEARE-Study-Group, Herzzentrum Ludwigshafen, Ludwigshafen, 
Germany
Background: Meta-analysis of randomised trials using GP IIb/IIIa receptor blocker (GP
IIb/IIIa) in acute coronary syndromes (ACS) indicated a significant reduction of mortality
at 30 days in diabetic patients (pts) with ACS undergoing PCI.
Methods: Since February 2002 the international Shakespeare Registry has been enroll-
ing consecutive patients undergoing PCI in 7 different countries in Europe to document
interventional and medical treatment as well as outcome in clinical practice. We exam-
ined the use of GP Ib/IIIa in diabetics versus non-diabetics with ACS in clinical practice in
Diabetics Non-diabetics
Odds ratio
(95 % C.I)
Odds ratio
(95 % C.I)
Nt-proBNP > 669 ng/L 3.4 (2.3-5.7) 1.9 (1.4-2.6)
St-depression > 0.5 mm 1.9 (1.1-3.3) 1.2 (0.8-1.7)
Troponin-T > 0.01 ug/L 1.7 (1.0-2.9) 1.6 (1.1-2.3)
Creatinine clearance < 51ml/min 1.7 (1.2-2.5) 2.1 (1.6-2.8)
Previous MI 1.7(1.2-2.5) 1.5 (1.2-2.0)
